2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserin
1997
Down-Regulation of the D1 and D5 Dopamine Receptors in the Primate Prefrontal Cortex by Chronic Treatment with Antipsychotic Drugs 1
Lidow M, Elsworth J, Goldman-Rakic P. Down-Regulation of the D1 and D5 Dopamine Receptors in the Primate Prefrontal Cortex by Chronic Treatment with Antipsychotic Drugs 1. Journal Of Pharmacology And Experimental Therapeutics 1997, 281: 597-603. PMID: 9103549, DOI: 10.1016/s0022-3565(24)36627-3.Peer-Reviewed Original ResearchConceptsChronic treatmentAntipsychotic drugsPrefrontal cortexReceptor antagonismDopamine receptorsD5 dopamine receptor mRNAD2 dopamine receptor antagonismD2 receptor antagonismDopamine receptor mRNAVehicle control groupTreatment of schizophreniaD1 classD5 dopamine receptorsDopamine receptor antagonismPrimate prefrontal cortexD5 mRNAsDopaminergic receptorsAntipsychotic medicationAntipsychotic efficacyD2 antagonistTherapeutic rangeAntipsychotic activityPharmacological spectrumReceptor mRNARibonuclease protection assays
1986
Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
Innis R, Bunney B, Charney D, Price L, Glazer W, Sternberg D, Rubin A, Heninger G. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Research 1986, 18: 1-7. PMID: 3737785, DOI: 10.1016/0165-1781(86)90056-9.Peer-Reviewed Original ResearchConceptsPsychosis ratingsPlacebo-controlled studyRole of cholecystokininCentral dopaminergic activityCCK receptor antagonistsPathogenesis of schizophreniaMesocortical neuronsNeuroleptic medicationNeurotransmitter statusReceptor antagonistDopaminergic activityAntipsychotic activitySchizophrenic patientsCholecystokininNegative findingsPreclinical researchProglumidePatientsSchizophreniaPotential reasonsMedicationsPathogenesisAntagonistMidbrainNeuropeptides
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply